92 related articles for article (PubMed ID: 20030503)
21.
Fatima GN; Maurya P; Nishtha ; Saraf SK
Curr Pharm Des; 2023; 29(40):3240-3253. PubMed ID: 37534480
[TBL] [Abstract][Full Text] [Related]
22. Dimeric ferulic acid conjugate as a prodrug for brain targeting after nasal administration of loaded solid lipid microparticles.
Botti G; Bianchi A; Dalpiaz A; Tedeschi P; Albanese V; Sorrenti M; Catenacci L; Bonferoni MC; Beggiato S; Pavan B
Expert Opin Drug Deliv; 2023; 20(11):1657-1679. PubMed ID: 38014509
[TBL] [Abstract][Full Text] [Related]
23. Intranasal Administration of a Polymeric Biodegradable Film to C57BL/6 Mice.
Balafas EG; Papakyriakopoulou PI; Kostomitsopoulos NG; Valsami GN
J Am Assoc Lab Anim Sci; 2023 Mar; 62(2):179-184. PubMed ID: 36898691
[TBL] [Abstract][Full Text] [Related]
24. A bioanalytical assay for estimation of thymoquinone in rats cerebrospinal fluid and brain tissues of nasally administrated thymoquinone loaded lipo-polymeric nanoshells and its pharmacokinetic profiling.
Trivedi S; Agade R; Belgamwar V
J Pharmacol Toxicol Methods; 2024; 127():107519. PubMed ID: 38797368
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic Study of Bioactive Glycopeptide from
Shikov AN; Pozharitskaya ON; Faustova NM; Kosman VM; Makarov VG; Razzazi-Fazeli E; Novak J
Mar Drugs; 2019 Oct; 17(10):. PubMed ID: 31614490
[TBL] [Abstract][Full Text] [Related]
26. Intranasal and intravenous apomorphine outperform ropinirole ocular drops for induction of emesis in dogs within ten minutes: a randomized, controlled clinical trial.
Manley SR; Berg AN; Rozanski EA; Sweigart BA; Lynch AM
J Am Vet Med Assoc; 2024 May; 262(5):635-639. PubMed ID: 38452486
[TBL] [Abstract][Full Text] [Related]
27. In Situ-Based Gels for Nose to Brain Delivery for the Treatment of Neurological Diseases.
Aderibigbe BA
Pharmaceutics; 2018 Mar; 10(2):. PubMed ID: 29601486
[TBL] [Abstract][Full Text] [Related]
28. Main Aspects of Pharmaceutical Development of In situ Immunobiological Drugs for Intranasal Administration.
E O B; I B M; V M K; N B D; T V G; Jr KII; I I K
Curr Pharm Biotechnol; 2023 Oct; ():. PubMed ID: 37842893
[TBL] [Abstract][Full Text] [Related]
29. Thermoreversible mucoadhesive in situ nasal gel for treatment of Parkinson's disease.
Rao M; Agrawal DK; Shirsath C
Drug Dev Ind Pharm; 2017 Jan; 43(1):142-150. PubMed ID: 27533244
[TBL] [Abstract][Full Text] [Related]
30. Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting.
Jafarieh O; Md S; Ali M; Baboota S; Sahni JK; Kumari B; Bhatnagar A; Ali J
Drug Dev Ind Pharm; 2015; 41(10):1674-81. PubMed ID: 25496439
[TBL] [Abstract][Full Text] [Related]
31. Development, characterization and application of in situ gel systems for intranasal delivery of tacrine.
Qian S; Wong YC; Zuo Z
Int J Pharm; 2014 Jul; 468(1-2):272-82. PubMed ID: 24709220
[TBL] [Abstract][Full Text] [Related]
32. Biomedical Trends in Stimuli-Responsive Hydrogels with Emphasis on Chitosan-Based Formulations.
Kruczkowska W; Gałęziewska J; Grabowska K; Liese G; Buczek P; Kłosiński KK; Kciuk M; Pasieka Z; Kałuzińska-Kołat Ż; Kołat D
Gels; 2024 Apr; 10(5):. PubMed ID: 38786212
[TBL] [Abstract][Full Text] [Related]
33. Nose to brain delivery of mirtazapine via lipid nanocapsules: Preparation, statistical optimization, radiolabeling, in vivo biodistribution and pharmacokinetic study.
Ibrahim MM; Basalious EB; El-Nabarawi MA; Makhlouf AI; Sayyed ME; Ibrahim IT
Drug Deliv Transl Res; 2024 Feb; ():. PubMed ID: 38376620
[TBL] [Abstract][Full Text] [Related]
34. Ion-activated
Lavania K; Garg A
Recent Adv Drug Deliv Formul; 2024; 18(1):35-49. PubMed ID: 38058093
[TBL] [Abstract][Full Text] [Related]
35. Thermoresponsive Gel-loaded Oxcarbazepine Nanosystems for Nose- To-Brain Delivery: Enhanced Antiepileptic Activity in Rats.
Abou-Taleb BA; El-Ganainy SO
Pharm Res; 2023 Jul; 40(7):1835-1852. PubMed ID: 37353628
[TBL] [Abstract][Full Text] [Related]
36. Quercetin Loaded Cationic Solid Lipid Nanoparticles in a Mucoadhesive In Situ Gel-A Novel Intravesical Therapy Tackling Bladder Cancer.
Shawky S; Makled S; Awaad A; Boraie N
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432718
[TBL] [Abstract][Full Text] [Related]
37. Nanotechnological Advances for Nose to Brain Delivery of Therapeutics to Improve the Parkinson Therapy.
Khatri DK; Preeti K; Tonape S; Bhattacharjee S; Patel M; Shah S; Singh PK; Srivastava S; Gugulothu D; Vora L; Singh SB
Curr Neuropharmacol; 2023; 21(3):493-516. PubMed ID: 35524671
[TBL] [Abstract][Full Text] [Related]
38. Development of a Cyclodextrin-Based Mucoadhesive-Thermosensitive In Situ Gel for Clonazepam Intranasal Delivery.
Cirri M; Maestrelli F; Nerli G; Mennini N; D'Ambrosio M; Luceri C; Mura PA
Pharmaceutics; 2021 Jun; 13(7):. PubMed ID: 34206967
[TBL] [Abstract][Full Text] [Related]
39. Thermosensitive Chitosan-
Rahmanian-Devin P; Baradaran Rahimi V; Askari VR
Adv Pharmacol Pharm Sci; 2021; 2021():6640893. PubMed ID: 34036263
[TBL] [Abstract][Full Text] [Related]
40. Microemulsion-Based Media in Nose-to-Brain Drug Delivery.
Froelich A; Osmałek T; Jadach B; Puri V; Michniak-Kohn B
Pharmaceutics; 2021 Feb; 13(2):. PubMed ID: 33540856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
